Table 3 Anti-tumour efficacy of SCOUT

From: Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer

Outcome, n (%)

Patients at all doses ( n =45)

MTD patients ( n =29)

Not assessablea

7

4

Evaluable patients

38

25

Complete response, n (%)b

0

0

Partial response, n (%)b

24 (63)

17 (68)

Stable disease, n (%)b

10 (26)

8 (32)

Disease control rate (95% CI)c

89 (75–97)

100 (86–100)

Progressive disease, n (%)b

4 (11)

0

Objective response rate (95% CI)

63 (46–78)

68 (46–85)

  1. CI=confidence interval; MTD=maximum tolerated dose.
  2. aPatients did not receive two treatment cycles and were thus not assessable for response.
  3. bBased on the number of evaluable patients.
  4. cComplete response+partial response+stable disease rates.
Back to article page